We believe this site might serve you best:

United States

United States

Choose language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

A Bioluminescent HDAC Assay for Cell-Based Drug Discovery Scientific Poster

SEARCH POSTERS

Abstract

Andrew L. Niles1, Nathan Evans1 and Thomas A. Kirkland2
1Promega Corporation, Madison, WI
2Promega Biosciences L.L.C., San Luis Obispo, CA

Cell-based models continue to be an important tool in the drug discovery and development toolbox because they provide a more biologically relevant context to study the complex changes occurring after targeted intervention. Histonedeacetylase (HDAC) enzymes are an emerging group of epigenetic modifiers that are of particular interest for targeted intervention because they are well-validated and chemically tractable. We have developed a bioluminescent, single addition, homogeneous deacetylase assay that is sufficiently sensitive and robust for cell-based screening or characterization efforts in either non-lytic or lytic formats. Here we describe efforts to define the utility of the assay using structurally diverse HDAC inhibitors with both attachment-dependent and suspension cell lines. Furthermore, HDAC inhibition will be correlated with cellular fate by various multiplexed viability and cytotoxicity measures in the same well.

Document Icon Download the poster PDF (216kb)

  • Part# PS117
  • Printed in USA.
Choose your country

Americas

Brazil
Canada
United States

Pacific Asia

Australia
India
Japan
Korea, Republic of
Singapore

Europe

Austria
Belgium
Denmark
Estonia
Finland
France
Germany
Iceland
Italy
Luxembourg
Netherlands
Norway
Poland
Spain
Sweden
Switzerland
United Kingdom